K. Bowman

发表

Oncogenic ERBB3 mutations in human cancers.

Somasekar Seshagiri, Jeremy Stinson, Charles Eigenbrot, 2013, Cancer cell.

Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding

Christian Wiesmann, Ping Wu, M. Tessier-Lavigne, 2007, The EMBO journal.

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

I. Mellman, Daniel J. Anderson, M. J. C. Ludlam, 2012, Proceedings of the National Academy of Sciences.

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Bioorganic & medicinal chemistry letters.

Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.

C. Ly, S. Sideris, S. Malek, 2011, Journal of medicinal chemistry.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

C. Ly, S. Sideris, S. Malek, 2012, Journal of medicinal chemistry.

Expression, purification, and characterization of deglycosylated human pro-prostate-specific antigen.

H. Zhan, K. Bowman, J. Clark, 2000, Protein expression and purification.

Semiautomated Small-Scale Purification Method for High-Throughput Expression Analysis of Recombinant Proteins.

Athena W Wong, Christine Kugel, Y. Franke, 2019, Methods in molecular biology.

Baculovirus display for discovery of low‐affinity extracellular receptor‐ligand interactions using protein microarrays (595.2)

A. Estevez, K. Bowman, Lino C. Gonzalez, 2014, Analytical biochemistry.

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

B. Peters, Z. Kan, S. Seshagiri, 2009, Cancer cell.

Crystal structure of human cathepsin V.

J. R. Somoza, M. Mcgrath, J. Palmer, 2000, Biochemistry.

Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers

Somasekar Seshagiri, Thomas D. Wu, Jeremy Stinson, 2012, Proceedings of the National Academy of Sciences.

Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.

K. Bowman, Jiansheng Wu, R. Firestein, 2016, ACS medicinal chemistry letters.

The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site.

Adam R. Johnson, Jianwen A. Feng, Lawren C. Wu, 2012, Structure.

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2016, Journal of medicinal chemistry.

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.

Belen Dominguez-Fernandez, C. Eigenbrot, Ivana Yen, 2015, Journal of medicinal chemistry.

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Adam R. Johnson, C. Eigenbrot, A. Estevez, 2016, ACS chemical biology.

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist

Jun Li, Christine Tam, Daniel F. Ortwine, 2015, Science.

Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation

Rekha S. Iyer, R. S. Iyer, M. Starovasnik, 2012, Proceedings of the National Academy of Sciences.

Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.

Philippe Bergeron, Kevin R Clark, James R Kiefer, 2016, ACS medicinal chemistry letters.

Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.

K. Bowman, Jiansheng Wu, R. Firestein, 2016, ACS medicinal chemistry letters.